JP2022542802A - 併用がん療法剤および方法 - Google Patents

併用がん療法剤および方法 Download PDF

Info

Publication number
JP2022542802A
JP2022542802A JP2022502209A JP2022502209A JP2022542802A JP 2022542802 A JP2022542802 A JP 2022542802A JP 2022502209 A JP2022502209 A JP 2022502209A JP 2022502209 A JP2022502209 A JP 2022502209A JP 2022542802 A JP2022542802 A JP 2022542802A
Authority
JP
Japan
Prior art keywords
cxcl9
tumor
cxcl10
polypeptide
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542802A5 (enExample
Inventor
ドゥビネット，スティーブン，エス．
リウ，ビン
リム，レイモンド
サレヒ－ラド，ラミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022542802A publication Critical patent/JP2022542802A/ja
Publication of JP2022542802A5 publication Critical patent/JP2022542802A5/ja
Priority to JP2025125676A priority Critical patent/JP2025166001A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022502209A 2019-07-17 2020-07-17 併用がん療法剤および方法 Pending JP2022542802A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025125676A JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875230P 2019-07-17 2019-07-17
US62/875,230 2019-07-17
PCT/US2020/042453 WO2021011844A2 (en) 2019-07-17 2020-07-17 Combination cancer therapy agents and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025125676A Division JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Publications (2)

Publication Number Publication Date
JP2022542802A true JP2022542802A (ja) 2022-10-07
JP2022542802A5 JP2022542802A5 (enExample) 2023-10-02

Family

ID=74209956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502209A Pending JP2022542802A (ja) 2019-07-17 2020-07-17 併用がん療法剤および方法
JP2025125676A Pending JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025125676A Pending JP2025166001A (ja) 2019-07-17 2025-07-28 併用がん療法剤および方法

Country Status (4)

Country Link
US (1) US20220280609A1 (enExample)
EP (1) EP3999092A4 (enExample)
JP (2) JP2022542802A (enExample)
WO (1) WO2021011844A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192323A1 (en) * 2021-03-09 2022-09-15 Board Of Regents, The University Of Texas System Low intensity ultrasound combination cancer therapies
WO2024103042A1 (en) * 2022-11-11 2024-05-16 University Of Florida Research Foundation, Incorporated Recombinant aav as an immune adjuvant
WO2025059507A1 (en) * 2023-09-15 2025-03-20 The Regents Of The University Of California Combination cancer therapy methods and agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191619A1 (en) * 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
JP2019519245A (ja) * 2016-06-30 2019-07-11 オンコラス， インコーポレイテッド ポリペプチド製剤の偽型腫瘍溶解性ウィルス送達

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160571A1 (en) * 2006-01-11 2007-07-12 Mitchell Krathwohl Composition and method for inducing protective vaccine response
RU2573912C2 (ru) * 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
US11236139B2 (en) * 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519245A (ja) * 2016-06-30 2019-07-11 オンコラス， インコーポレイテッド ポリペプチド製剤の偽型腫瘍溶解性ウィルス送達
WO2018191619A1 (en) * 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCAND. J. IMMUNOL., vol. vol.65, issue 1, JPN6024026269, 2007, pages 8 - 13, ISSN: 0005561000 *

Also Published As

Publication number Publication date
EP3999092A2 (en) 2022-05-25
EP3999092A4 (en) 2023-08-09
WO2021011844A2 (en) 2021-01-21
WO2021011844A9 (en) 2021-04-01
US20220280609A1 (en) 2022-09-08
JP2025166001A (ja) 2025-11-05
WO2021011844A3 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
Zhu et al. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
US20250313803A1 (en) Compositions and Methods for Cancer Immunotherapy
JP2025166001A (ja) 併用がん療法剤および方法
WO2020030016A1 (en) Combination of immunotherapies with mdm2 inhibitors
US20240408139A1 (en) Engineered cytokine receptors for tunable adoptive cell therapy
TWI869476B (zh) 用以治療癌症的醫藥、組合醫藥、ｔ細胞、及核酸輸送組成物
WO2018009972A1 (en) Chimeric antigen receptor modified t cells
Pérez-Lorenzo et al. Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma
KR20230088768A (ko) 췌관 샘암종 치료를 위한 병용 면역치료학적 방법 및 조성물
JP7407452B2 (ja) がんの治療及び／又は予防のための医薬
WO2025059507A1 (en) Combination cancer therapy methods and agents
HK40033024B (en) Compositions and methods for cancer immunotherapy
HK40033024A (en) Compositions and methods for cancer immunotherapy
HK40074698A (en) Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product
Freeman et al. Principles of Combination Immunotherapies
NZ750663B2 (en) Compositions and methods for cancer immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250908